Cambiogenplasmid
| Gene therapy | |
|---|---|
| Target gene | VEGF |
| Vector | Plasmid |
| Clinical data | |
| Trade names | Neovasculgen |
| Other names | Pl-VEGF165 |
| Routes of administration | Intraneural injection |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF).[1][2] Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF.[3][4] It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.
References
[edit]- ^ "Vascular endothelial growth factor gene therapy - HSCI". Adis Insight. Springer Nature Switzerland AG.
- ^ "Gene Therapy for PAD Approved". Drug Discovery and Development. 6 December 2011. Archived from the original on 3 September 2015. Retrieved 5 August 2015.
- ^ "Neovasculogen listing in Eurolab". Eurolab. Retrieved 4 August 2015.
- ^ Deev RV, Bozo IY, Mzhavanadze ND, Voronov DA, Gavrilenko AV, Chervyakov YV, et al. (September 2015). "pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia". Journal of Cardiovascular Pharmacology and Therapeutics. 20 (5): 473–82. doi:10.1177/1074248415574336. PMID 25770117. S2CID 13443907.
See also
[edit] | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |